Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents.
Authors: Starčević K,Pešić D,Toplak A,Landek G,Alihodžić S,Herreros E,Ferrer S,Spaventi R,Perić M,
Address: GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.
Journal: Eur J Med Chem.
Publication: 2012 Mar;49:365-78. doi: 10.1016/j.ejmech.2012.01.039. Epub 2012 Jan 26.
Malaria remains the most prevalent tropical disease, and due to the spread of resistant parasites Novel therapeutics are urgently needed. Azithromycin has shown potential in malaria treatment so we designed hybrid azalide molecules with the aim to improve activity against and selectivity for the malaria parasite. Novel hybrid molecules comprising 4-aminoquinoline moiety covalently liked to 15-membered azalide scaffold at position C-3' were synthesized and biologically evaluated. antimalarial testing against Plasmodium falciparum sensitive and resistant strains confirmed the improved in vitro activity over azithromycin and chloroquine. Selectivity of the compounds (HepG2 IC(50)/P. falciparum IC(50) ratio) for the parasite was high (100-2700) and their antibacterial activity diminished. Even though oral bioavailability determined for compound 12 was low, novel quinoline C-3'-substituted 15-membered azalides represent an interesting subclass of antimalarial macrolides that need further research and evaluation.
Copyright Â© 2012. Published by Elsevier Masson SAS.
The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.